| Acquired by | Roche Holding |
| Price | $143M |
| Date | 7/08 |
| Website | ariusresearch.com |
| Category | BioTech |
| Phone | 416-862-2323 |
| Employees | |
| Founded | 1999 |
| TOTAL | $23.5M |
| VENTURE FUNDING TOTAL | $23.5M |
| Venture Round, 11/05 Xmark Asset Management | $2M |
| Venture Round, 3/06 OrbiMed Advisors Xmark Opportunity Funds Efficacy Capital | $21.5M |
ARIUS Research, Inc., a biotechnology company, engages in the discovery and development of antibody therapeutics primarily focusing on breast, prostate, ovarian, colorectal, pancreatic and lung cancers, leukemia, and melanoma. It identifies monoclonal antibodies targeting various cancer indications through its technology platform, FunctionFIRST. The company’s product pipeline includes CD63 program that is in preclinical studies for various cancer indications; ARH460-16-2, an antibody targeting the cancer stem cell antigen CD44; AR36A36.11.1 and AR10A304.7, which targets the complement-inhibitory molecule CD59; AR47A6.4.2 and AR52A301.5, which are monoclonal antibodies directed to the cancer-associated protein TROP-2 that is homologous to human EpCAM, an another cell surface cancer related protein; and AR40A746.2.3 that targets leukemia cancer stem cells. It also has antibody programs targeting the MCSP antigen and 37LRP. ARIUS has partnerships with Oxford BioMedica plc, Xerion Pharmaceuticals AG, PDL BioPharma, Inc., Medarex, Inc., Genentech, Inc., and Takeda Pharmaceutical Company Limited. The company was founded in 1999 and is based in Toronto, Canada. As of September 23, 2008, Arius Research Inc. operates as a subsidiary of Roche Holding AG.
